10x Genomics, Inc.

13.34-0.25 (-1.84%)
Oct 28, 4:00:00 PM EDT · NasdaqGS · TXG · USD

Upcoming Earnings

Report date
Nov 6, 2025 (in 8 days)

Key Stats

Market Cap
1.66B
P/E (TTM)
-
Basic EPS (TTM)
-0.70
Dividend Yield
0%

Recent Filings

About

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the Americas, Europe, the Middle East, Africa, China, and the Asia Pacific. It offers Chromium platform that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; Visium platform includes Spatial Gene Expression, HD Spatial Gene Expression, and Spatial Gene and Protein Expression assays, as well as the Visium CytAssist, an instrument designed to simplify and optimize the Visium solution workflow by facilitating the transfer of transcriptomic analytes from standard glass slides to Visium slides; and Xenium Analyzer instrument enables researchers to detect and preserve the cellular location of hundreds of RNA targets directly in a fresh frozen or FFPE tissue section. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

CEO
Dr. Serge Saxonov Ph.D.
IPO
9/12/2019
Employees
1,306
Sector
Healthcare
Industry
Health Information Services